Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Free Report) in a research report sent to investors on Friday ...

Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given an average rating of “Hold” by the seven analysts that are presently covering the company, Marketbeat.com reports. Seven analysts ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

As the year comes to a close, the overall level of global mergers and acquisitions activity in 2024 is expected to be $3.5 ...

Pharmaceutical Cartridges Market Driven by rising demand for self-administered therapies & advanced drug delivery systems, the <a target ...

A large pharmaceutical company collaborated with DelveInsight to evaluate CDMO companies for API and FD development. DelveInsight provided a comprehensive one-time report benchmarking top contract ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Research projects that generative AI could boost the pharma and medical-product industries' annual revenues by up to $110 ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.